One or two doses of psilocybin, a compound found in psychedelic mushrooms, may improve the mental health of cancer patients when accompanied by psychotherapy, a new study suggests. A second new study ...

Geode Capital Management LLC boosted its holdings in Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Free Report) by 10.8% during ...

GET MORE AI-GENERATED SIGNALS: December 29, 2024, 13:56 pm ET, BY John- Contributor| Editor: Thomas H. Kee Jr. ( Follow on ...

Inc. (NASDAQ:MNMD – Get Free Report) shares were down 8.5% on Friday following insider selling activity. The company traded ...

On Friday, Mind Medicine (MindMed) Inc (MNMD) stock saw a decline, ending the day at $6.84 which represents a decrease of $-0.79 or -10.35% from the prior close of $7.63. The stock opened at $7.57 and ...

在其他最近的新闻中，生物制药公司Mind Medicine (MindMed)有了重大进展。该公司用于治疗广泛性焦虑障碍的实验性治疗MM120 ODT获得了英国药品和保健品监管局的创新通行证。MindMed还进行了关键的高管任命，欢迎Javier A. Muniz博士担任研发战略副总裁，Gregg A. Pratt博士担任首席监管和质量保证官。

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD)的首席医疗官Dan Karlin最近出售了公司6,643股普通股。该公司是一家市值5.02亿美元的生物科技公司，其股票在过去一年中上涨超过100%。根据 InvestingPro 的数据，分析师对MNMD保持看好态度，多项关键指标显示公司财务状况良好。这次出售是在2024年12月26日执行的，属于根据规则10b5- ...

Lysergic acid diethylamide is under clinical development by Mind Medicine MindMed and currently in Phase II for Major Depressive Disorder.

MNMD is developing its lead pipeline candidate, MM120, an orally disintegrating tablet (ODT) and a pharmaceutically optimized ...

In a recent transaction, Robert Barrow, the Chief Executive Officer of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), sold a total of 15,659 common shares of the company. The sale,... Mind Medicine ...

Mind Medicine Inc., also known as MindMed, is a New York-based psychedelic medicine biotech company that develops psychedelic-inspired medicines known as psychoplastogens and therapies to address ...